1. Show article details.

    BRIEF-Myokardia Announces Appointment Of Denelle J. Waynick As General Counsel And Corporate Secretary

    Reuters – 8:21 AM ET 07/06/2020

    MyoKardia Inc (MYOK): * MYOKARDIA ANNOUNCES APPOINTMENT OF DENELLE J. WAYNICK AS GENERAL COUNSEL AND CORPORATE SECRETARY Source text for Eikon: Further company coverage:

  2. Show article details.

    MyoKardia Announces Appointment of Denelle J. Waynick as General Counsel and Corporate Secretary

    GlobeNewswire – 8:00 AM ET 07/06/2020

    MyoKardia, Inc. (MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Cynthia Ladd, who has been leading MyoKardia’s legal function as General Counsel since January 2018, will be retiring this year. “Denelle is a great leader, with an enterprise mindset, hands-on style and deep focus on people and their development.

  3. Show article details.

    BRIEF-Myokardia Inc - Plans To Start Phase 2 Genetic Dcm Study In Second Half Of 2020

    Reuters – 8:47 AM ET 06/22/2020

    MyoKardia Inc (MYOK): * MYOKARDIA ANNOUNCES POSITIVE DATA FROM PHASE 2A CLINICAL TRIAL OF DANICAMTIV PRESENTED AT ESC’S HFA DISCOVERIES WITH SIMULTANEOUS PUBLICATION IN EUROPEAN JOURNAL OF HEART FAILURE. * MYOKARDIA (MYOK) - NEW OBSERVATIONS SHOW IMPROVEMENTS IN LEFT ATRIAL VOLUME AND FUNCTION, KEY PROGNOSTIC INDICATORS OF ATRIAL FIBRILLATION.

  4. Show article details.

    MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure

    GlobeNewswire – 8:00 AM ET 06/22/2020

    Danicamtiv was Well Tolerated; Demonstrated Improvements in Cardiac Contractility and Preserved Diastolic Function in Patients with Stable Heart Failure with Reduced Ejection Fraction New Observations Show Improvements in Left Atrial Volume and Function, Key Prognostic Indicators of Atrial Fibrillation Additional Nonclinical Studies Also Presented Demonstrating Danicamtiv’s Differentiated Mech...

  5. Show article details.

    BRIEF-MyoKardia Presents Danicamtiv Data At European Society Of Cardiology's Virtual Heart Failure Association Discoveries

    Reuters – 8:38 AM ET 06/19/2020

    MyoKardia Inc (MYOK): * MYOKARDIA ANNOUNCES DANICAMTIV DATA PRESENTATION AT THE EUROPEAN SOCIETY OF CARDIOLOGY’S VIRTUAL HEART FAILURE ASSOCIATION DISCOVERIES Source text for Eikon: Further company coverage:

  6. Show article details.

    MyoKardia Announces Danicamtiv Data Presentation at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries

    GlobeNewswire – 8:30 AM ET 06/19/2020

    -- MyoKardia (MYOK) to Host Conference Call at 8:30 a.m. ET on Monday, June 22, 2020 -- MyoKardia (MYOK), Inc. today announced that data from the company’s Phase 2a multiple-ascending dose study of danicamtiv in patients with chronic heart failure with reduced ejection fraction will be presented in a late-breaker session at the European Society of Cardiology’s Virtual Heart Failure Association Discoveries ev...

  7. Show article details.

    MyoKardia to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference

    GlobeNewswire – 8:00 AM ET 06/16/2020

    MyoKardia, Inc. (MYOK) today announced that Tassos Gianakakos, Chief Executive Officer, will participate in a fireside chat at the virtual BMO 2020 Prescriptions for Success Healthcare Conference on Tuesday, June 23rd, 2020 at 10:30 a.m. ET.

  8. Show article details.

    BRIEF-Myokardia Announces Pricing Of Public Offering Of Common Stock

    Reuters – 2:12 AM ET 05/13/2020

    MyoKardia Inc (MYOK): * MYOKARDIA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK. * MyoKardia Inc (MYOK) - PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 5,250,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $105.00 PER SHARE Source text for Eikon: Further company coverage:

  9. Show article details.

    MyoKardia Announces Pricing of Public Offering of Common Stock

    GlobeNewswire – 9:34 PM ET 05/12/2020

    MyoKardia (MYOK), Inc. , a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $105.00 per share, before underwriting discounts.

  10. Show article details.

    BRIEF-MyoKardia Announces Proposed Public Offering Of Common Stock

    Reuters – 7:05 PM ET 05/11/2020

    MyoKardia Inc (MYOK): * MYOKARDIA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK. * MyoKardia Inc (MYOK) - COMMENCED A PROPOSED UNDERWRITTEN PUBLIC OFFERING TO SELL $450.0 MILLION IN SHARES OF ITS COMMON STOCK.

  11. Show article details.

    MyoKardia Announces Proposed Public Offering of Common Stock

    GlobeNewswire – 4:02 PM ET 05/11/2020

    MyoKardia, Inc. (MYOK), a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, today announced that it has commenced a proposed underwritten public offering to sell $450.0 million in shares of its common stock.

  12. Show article details.

    BRIEF-MyoKardia Announces Primary, All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten

    Reuters – 7:41 AM ET 05/11/2020

    MyoKardia Inc (MYOK): * MYOKARDIA ANNOUNCES PRIMARY AND ALL SECONDARY ENDPOINTS MET IN PHASE 3 EXPLORER CLINICAL TRIAL OF MAVACAMTEN FOR THE TREATMENT OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY. * MYOKARDIA ANNOUNCES PRIMARY AND ALL SECONDARY ENDPOINTS MET IN PHASE 3 EXPLORER CLINICAL TRIAL OF MAVACAMTEN FOR THE TREATMENT OF OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY.

  13. Show article details.

    MyoKardia Announces Primary and All Secondary Endpoints Met in Phase 3 EXPLORER Clinical Trial of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy

    GlobeNewswire – 7:30 AM ET 05/11/2020

    Highly Statistically Significant Improvements in NYHA Classification, Peak VO2, and LVOT Gradient Observed vs.

  14. Show article details.

    MyoKardia Reports First Quarter 2020 Financial Results

    GlobeNewswire – 4:05 PM ET 05/06/2020

    MyoKardia, Inc. (MYOK), today reported financial results for the first quarter ended March 31, 2020. “Our team has continued to drive toward our mission, despite the extraordinary personal and professional disruptions introduced by the COVID-19 pandemic.

  15. Show article details.

    MyoKardia Announces Mavacamten Treatment Well Tolerated and Significantly Reduced Biomarkers of Cardiac Injury and Wall Stress in Non-Obstructive Hypertrophic Cardiomyopathy Patients

    GlobeNewswire – 10:30 AM ET 03/30/2020

    MAVERICK-HCM Phase 2 Clinical Trial Results Consistent with Tolerability Observations from Prior Studies of Mavacamten Improvement in NT-proBNP and Troponin Levels Support Future Development in Non-Obstructive HCM and Heart Failure with Preserved Ejection Fraction MyoKardia (MYOK) to Host Webcast Conference Call at 4:30 p.m. EDT BRISBANE, Calif., March 30, 2020 -- MyoKardia (MYOK), Inc. today announced resul...

  16. Show article details.

    MyoKardia Provides Clinical Trial Update in the Context of the COVID-19 Pandemic

    GlobeNewswire – 8:30 AM ET 03/26/2020

    MyoKardia, Inc. (MYOK) today provided an update to the status of its clinical programs in the context of the COVID-19 pandemic given the impact of the pandemic on the global healthcare system’s present ability to support the conduct of clinical trials.

  17. Show article details.

    Data from MAVERICK-HCM Study of Mavacamten in Non-Obstructive Hypertrophic Cardiomyopathy Selected for Virtual Late-Breaker Presentation at the American College of Cardiology’s 69th Annual Scientific Session Together with World Congress of Cardiology

    GlobeNewswire – 4:45 PM ET 03/19/2020

    MyoKardia, Inc. (MYOK) today announced that the company will be presenting data from its Phase 2 MAVERICK-HCM clinical trial during a late-breaker session at the upcoming American College of Cardiology’s 69th Annual Scientific Session together with the World Congress of Cardiology.

  18. Show article details.

    MyoKardia Reports Fourth Quarter and Full Year 2019 Financial Results

    GlobeNewswire – 4:05 PM ET 02/27/2020

    MyoKardia, Inc. (MYOK), today reported financial results for the fourth quarter and full year ended December 31, 2019. “MyoKardia (MYOK) achieved significant progress in 2019, advancing our pipeline and regaining global rights to our entire portfolio.

  19. Show article details.

    MyoKardia to Present at 40th Annual Cowen Health Care Conference

    GlobeNewswire – 8:00 AM ET 02/24/2020

    MyoKardia, Inc. (MYOK), today announced that Taylor Harris, Chief Financial Officer, will present at the 40th Annual Cowen Health Care Conference on Monday, March 2nd 2020 at 1:30 p.m. EST in Boston.

  20. Show article details.

    MyoKardia to Report Fourth Quarter and Full Year 2019 Financial Results on Thursday, February 27, 2020

    GlobeNewswire – 8:00 AM ET 02/20/2020

    MyoKardia, Inc. (MYOK), today announced that it will report fourth quarter and full year 2019 financial and operating results on Thursday, February 27, 2020. Conference Call and WebcastAnalysts and investors are invited to participate in the conference call by calling 844-494-0193 from the U.S. and Canada or 508-637-5584 internationally and using the conference ID 8698045.

Page:

Today's and Upcoming Events

  • Aug
    05

    MYOK to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    06

    MYOK announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.